Miriam Motlak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miriam Motlak has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Gerardo Guilarte
Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
5 shared publications - Sonal Choudhary
Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
5 shared publications Gerardo Guilarte
Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
3 shared publicationsSonal Choudhary
3 shared publicationsConnor Gill
2 shared publications- Dongwon Lee
Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (11)
Peptides as Cosmeceuticals for Post‐Procedural Wound Healing: A Systematic Review
Background: Topical peptides have emerged as a promising cosmeceutical for indications ranging from hyperpigmentation to anti‐aging. However, their role in post‐procedural wound healing following aesthetic interventions remains underexplored. Aims: The aim of this study was to systematically evaluate the evidence supporting the use of topical peptide formulations in enhancing post‐procedural wound healing and patient recovery outcomes. Methods: A systematic review was conducted to identify clinical studies evaluating topical peptide application following aesthetic dermatologic procedures, including radiofrequency microneedling and non‐ablative laser therapies. Eligible studies assessed both cosmetic and therapeutic outcomes related to wound healing and recovery. Results: Six studies met inclusion criteria across three peptide systems and across ablative laser, nonablative laser, hybrid laser, and radiofrequency microneedling procedures. Peptide formulations following ablative procedures were associated with improvements in exudation, crusting, and epithelial confluence, whereas nonablative procedures demonstrated reduced erythema and improved patient‐reported recovery outcomes, including enhanced skin appearance and texture. Studies of hybrid fractional resurfacing and radiofrequency microneedling similarly reported improvements in selected early recovery outcomes. Conclusion: Topical peptide formulations show potential as adjunctive therapies for improving post‐procedural recovery following aesthetic dermatologic procedures. However, available evidence is limited by varying procedural modalities, small sample sizes, short follow‐up intervals, and restricted demographic diversity. Larger randomized controlled trials with broader representation across Fitzpatrick skin types are necessary to better define the clinical role of topical peptide cosmeceuticals in post‐procedural wound healing.
- 9 November 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (11)
Open AccessPeptides as Cosmeceuticals for Post‐Procedural Wound Healing: A Systematic Review
Background: Topical peptides have emerged as a promising cosmeceutical for indications ranging from hyperpigmentation to anti‐aging. However, their role in post‐procedural wound healing following aesthetic interventions remains underexplored. Aims: The aim of this study was to systematically evaluate the evidence supporting the use of topical peptide formulations in enhancing post‐procedural wound healing and patient recovery outcomes. Methods: A systematic review was conducted to identify clinical studies evaluating topical peptide application following aesthetic dermatologic procedures, including radiofrequency microneedling and non‐ablative laser therapies. Eligible studies assessed both cosmetic and therapeutic outcomes related to wound healing and recovery. Results: Six studies met inclusion criteria across three peptide systems and across ablative laser, nonablative laser, hybrid laser, and radiofrequency microneedling procedures. Peptide formulations following ablative procedures were associated with improvements in exudation, crusting, and epithelial confluence, whereas nonablative procedures demonstrated reduced erythema and improved patient‐reported recovery outcomes, including enhanced skin appearance and texture. Studies of hybrid fractional resurfacing and radiofrequency microneedling similarly reported improvements in selected early recovery outcomes. Conclusion: Topical peptide formulations show potential as adjunctive therapies for improving post‐procedural recovery following aesthetic dermatologic procedures. However, available evidence is limited by varying procedural modalities, small sample sizes, short follow‐up intervals, and restricted demographic diversity. Larger randomized controlled trials with broader representation across Fitzpatrick skin types are necessary to better define the clinical role of topical peptide cosmeceuticals in post‐procedural wound healing.
- Open Access
- 7 October 2026
- Published by Elsevier in JAAD International
- Vol. 29, 152-155
Supplement and fermented food use among older US adults with dermatologic disorders: A cross-sectional analysis
- 7 October 2026
- Published by Elsevier in JAAD International
- Vol. 29, 152-155
Open AccessSupplement and fermented food use among older US adults with dermatologic disorders: A cross-sectional analysis
- Open Access
- 7 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71184
Omega Fatty Acids in Hair Loss Disorders: A Scoping Review of Preclinical and Clinical Evidence
Background: Omega fatty acids, including polyunsaturated omega‐3 and omega‐6 fatty acids (PUFAs) and monounsaturated omega‐9 fatty acids, regulate inflammation, cellular signaling, and tissue homeostasis, and may influence hair follicle biology and hair growth. The widespread use of dietary supplements for hair loss has been fueled by increasing consumer interest and the rapid spread of health information on social media. Aims: This scoping review synthesizes preclinical and clinical evidence on the role of omega fatty acids in the management of alopecia. Methods: PubMed, Embase, ClinicalTrials.gov , the Cochrane Library, and Ovid MEDLINE were searched from database inception through February 2, 2026. The review was conducted in accordance with the PRISMA‐ScR. Eligible studies were peer‐reviewed, English‐language studies evaluating the relationship between omega fatty acids and hair growth, hair loss, or hair follicle biology in scarring or nonscarring alopecia. Results: Preclinical studies suggest that omega fatty acids may promote dermal papilla cell proliferation, activate signaling pathways involved in hair follicle growth, suppress mediators of androgen‐driven hair loss, and may protect against chemotherapy‐induced follicular apoptosis. Clinical studies have reported improvements in hair density, hair growth, and reduced shedding, although many studies evaluated combination nutritional supplements rather than omega fatty acids alone. In contrast, one clinical study of men with androgenetic alopecia found that higher omega‐3 intake was associated with a lower likelihood of clinical improvement. Limited clinical evidence also suggests that omega fatty acid supplementation may support hair regrowth in alopecia areata through immunomodulatory and anti‐inflammatory effects. Conclusion: Current data do not support omega fatty acid supplementation as a standalone treatment for any alopecia subtype.
- 7 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71184
Open AccessOmega Fatty Acids in Hair Loss Disorders: A Scoping Review of Preclinical and Clinical Evidence
Background: Omega fatty acids, including polyunsaturated omega‐3 and omega‐6 fatty acids (PUFAs) and monounsaturated omega‐9 fatty acids, regulate inflammation, cellular signaling, and tissue homeostasis, and may influence hair follicle biology and hair growth. The widespread use of dietary supplements for hair loss has been fueled by increasing consumer interest and the rapid spread of health information on social media. Aims: This scoping review synthesizes preclinical and clinical evidence on the role of omega fatty acids in the management of alopecia. Methods: PubMed, Embase, ClinicalTrials.gov , the Cochrane Library, and Ovid MEDLINE were searched from database inception through February 2, 2026. The review was conducted in accordance with the PRISMA‐ScR. Eligible studies were peer‐reviewed, English‐language studies evaluating the relationship between omega fatty acids and hair growth, hair loss, or hair follicle biology in scarring or nonscarring alopecia. Results: Preclinical studies suggest that omega fatty acids may promote dermal papilla cell proliferation, activate signaling pathways involved in hair follicle growth, suppress mediators of androgen‐driven hair loss, and may protect against chemotherapy‐induced follicular apoptosis. Clinical studies have reported improvements in hair density, hair growth, and reduced shedding, although many studies evaluated combination nutritional supplements rather than omega fatty acids alone. In contrast, one clinical study of men with androgenetic alopecia found that higher omega‐3 intake was associated with a lower likelihood of clinical improvement. Limited clinical evidence also suggests that omega fatty acid supplementation may support hair regrowth in alopecia areata through immunomodulatory and anti‐inflammatory effects. Conclusion: Current data do not support omega fatty acid supplementation as a standalone treatment for any alopecia subtype.
- 7 September 2026
- Published by Elsevier in Acta Astronautica
- Vol. 250, 163-174
Cutaneous changes associated with spaceflight and spaceflight analogs: A scoping review
- 7 September 2026
- Published by Elsevier in Acta Astronautica
- Vol. 250, 163-174
Cutaneous changes associated with spaceflight and spaceflight analogs: A scoping review
- Open Access
- 2 August 2026
- Published by SAGE Publications in Public Health Reports®
Tattoo Ink as a Chronic Intradermal Chemical Exposure: A Policy and Research Agenda for US Regulation
Tattooing injects pigments into the dermis, creating intradermal chemical exposure that can trigger delayed inflammatory reactions and, in some cases, systemic immune manifestations. About 32% of US adults report at least 1 tattoo, highlighting the need for prevention and accurate counseling. This topical review summarizes tattoo ink–associated harms and outlines US policy and research priorities. We synthesized regulatory documents and selected literature, including the Modernization of Cosmetics Regulation Act (MoCRA), US Food and Drug Administration (FDA) guidance and safety communications on tattoo inks, Council of Europe resolutions, and the European Union Registration, Evaluation, Authorization, and Restriction of Chemicals (EU REACH) restriction. We screened reference lists for additional sources to link clinical risk signals to actionable policy levers. Despite ink’s persistence in tissue, in the United States, federal oversight largely follows a cosmetic framework, while local regulation emphasizes studio hygiene. Recent US regulatory changes, including MoCRA and FDA guidance on tattoo contamination, strengthen postmarket authority and contamination control but still lack enforceable composition limits for intradermal, long-term exposure. Key gaps include inconsistent ingredient disclosure, limited batch/lot traceability, and the absence of a national tattoo adverse event registry. By contrast, EU REACH pairs chemical restrictions with labeling that supports ingredient transparency and batch identification. Priorities include enforceable composition limits, standardized disclosure with batch traceability, and a clinician-led registry to improve signal detection and patient counseling. Clinicians can support these reforms by documenting tattoo exposures, reporting suspected ink-related adverse events, and engaging professional societies to inform regulators and shape practical standards.
- 2 August 2026
- Published by SAGE Publications in Public Health Reports®
Open AccessTattoo Ink as a Chronic Intradermal Chemical Exposure: A Policy and Research Agenda for US Regulation
Tattooing injects pigments into the dermis, creating intradermal chemical exposure that can trigger delayed inflammatory reactions and, in some cases, systemic immune manifestations. About 32% of US adults report at least 1 tattoo, highlighting the need for prevention and accurate counseling. This topical review summarizes tattoo ink–associated harms and outlines US policy and research priorities. We synthesized regulatory documents and selected literature, including the Modernization of Cosmetics Regulation Act (MoCRA), US Food and Drug Administration (FDA) guidance and safety communications on tattoo inks, Council of Europe resolutions, and the European Union Registration, Evaluation, Authorization, and Restriction of Chemicals (EU REACH) restriction. We screened reference lists for additional sources to link clinical risk signals to actionable policy levers. Despite ink’s persistence in tissue, in the United States, federal oversight largely follows a cosmetic framework, while local regulation emphasizes studio hygiene. Recent US regulatory changes, including MoCRA and FDA guidance on tattoo contamination, strengthen postmarket authority and contamination control but still lack enforceable composition limits for intradermal, long-term exposure. Key gaps include inconsistent ingredient disclosure, limited batch/lot traceability, and the absence of a national tattoo adverse event registry. By contrast, EU REACH pairs chemical restrictions with labeling that supports ingredient transparency and batch identification. Priorities include enforceable composition limits, standardized disclosure with batch traceability, and a clinician-led registry to improve signal detection and patient counseling. Clinicians can support these reforms by documenting tattoo exposures, reporting suspected ink-related adverse events, and engaging professional societies to inform regulators and shape practical standards.
- 9 July 2026
- Published by Wiley in Developmental Dynamics
The hypermobility crisis: A review and call to action
Hypermobile Ehlers–Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) are common yet underrecognized connective tissue disorders characterized by joint hypermobility and multi‐organ system involvement. Current diagnostic criteria inadequately capture the clinical heterogeneity of hEDS/HSD. Consequently, patients often face diagnostic delays and fragmented care, which exacerbate underlying comorbidities such as chronic pain and psychological distress. This narrative review explores the key limitations of existing diagnostic criteria, the burden of underrecognized comorbidities, and systemic barriers to health care access. We then propose actionable recommendations for clinicians, professional societies, educators, and researchers to standardize diagnostic practices, expand education and training, and invest in multi‐site patient registries and large‐scale genetic studies. Coordinated action is needed to build evidence‐based, patient‐centered care systems that recognize and address the full complexity of hEDS and HSD.
- 9 July 2026
- Published by Wiley in Developmental Dynamics
The hypermobility crisis: A review and call to action
Hypermobile Ehlers–Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) are common yet underrecognized connective tissue disorders characterized by joint hypermobility and multi‐organ system involvement. Current diagnostic criteria inadequately capture the clinical heterogeneity of hEDS/HSD. Consequently, patients often face diagnostic delays and fragmented care, which exacerbate underlying comorbidities such as chronic pain and psychological distress. This narrative review explores the key limitations of existing diagnostic criteria, the burden of underrecognized comorbidities, and systemic barriers to health care access. We then propose actionable recommendations for clinicians, professional societies, educators, and researchers to standardize diagnostic practices, expand education and training, and invest in multi‐site patient registries and large‐scale genetic studies. Coordinated action is needed to build evidence‐based, patient‐centered care systems that recognize and address the full complexity of hEDS and HSD.
- Open Access
- 2 June 2026
- Published by Elsevier in JAAD Reviews
- Vol. 9, 87-89
Alopecia in hijab-wearing patients: A systematic review
- 2 June 2026
- Published by Elsevier in JAAD Reviews
- Vol. 9, 87-89
Open AccessAlopecia in hijab-wearing patients: A systematic review
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Tattoo Exposure and Immune‐Mediated Disease: Clinical Patterns, Latency, and Mechanisms: A Systematic Review
Tattoos are increasingly prevalent worldwide, yet links between tattoo pigment exposure and immune‐mediated disease remain incompletely defined. We performed a systematic review of MEDLINE (PubMed), Embase, and the Cochrane Library to characterize clinical phenotypes, latency, pigment features, histopathology, systemic involvement, and proposed mechanisms of tattoo‐associated immune‐mediated reactions. We included case reports, case series, and observational studies describing immune‐mediated reactions temporally associated with tattoo placement and extracted data on pigment color, time to onset, extracutaneous manifestations, and outcomes, with study‐level risk‐of‐bias assessment. We included 101 studies: 93 descriptive reports (101 individual cases) and eight comparative observational studies. Reactions clustered into reproducible clinicopathologic phenotypes, most commonly sarcoid‐like/granulomatous, followed by lichenoid/lichen planus‐like, lupus/scleroderma‐like, and other immune‐mediated patterns. Among 68 cases with temporal data, the median latency from tattooing to reaction onset was 75 days (range, 1–4200 days). Pigment‐phenotype associations were consistent: Black pigment predominated in granulomatous and lupus/scleroderma‐like reactions, whereas red pigment was most often associated with lichenoid reactions. Systemic involvement was reported in approximately half of the cases, most frequently pulmonary or ocular. Granulomatous inflammation was the dominant histologic pattern and was often accompanied by regional lymph node pigment deposition. Although causality and population‐level risk cannot be determined from largely descriptive data, recognition of phenotype‐ and color‐associated patterns may guide evaluation, including consideration of sarcoidosis screening in papulonodular black tattoo reactions, and supports the development of prospective registries incorporating standardized clinical and pigment‐analytic data.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessTattoo Exposure and Immune‐Mediated Disease: Clinical Patterns, Latency, and Mechanisms: A Systematic Review
Tattoos are increasingly prevalent worldwide, yet links between tattoo pigment exposure and immune‐mediated disease remain incompletely defined. We performed a systematic review of MEDLINE (PubMed), Embase, and the Cochrane Library to characterize clinical phenotypes, latency, pigment features, histopathology, systemic involvement, and proposed mechanisms of tattoo‐associated immune‐mediated reactions. We included case reports, case series, and observational studies describing immune‐mediated reactions temporally associated with tattoo placement and extracted data on pigment color, time to onset, extracutaneous manifestations, and outcomes, with study‐level risk‐of‐bias assessment. We included 101 studies: 93 descriptive reports (101 individual cases) and eight comparative observational studies. Reactions clustered into reproducible clinicopathologic phenotypes, most commonly sarcoid‐like/granulomatous, followed by lichenoid/lichen planus‐like, lupus/scleroderma‐like, and other immune‐mediated patterns. Among 68 cases with temporal data, the median latency from tattooing to reaction onset was 75 days (range, 1–4200 days). Pigment‐phenotype associations were consistent: Black pigment predominated in granulomatous and lupus/scleroderma‐like reactions, whereas red pigment was most often associated with lichenoid reactions. Systemic involvement was reported in approximately half of the cases, most frequently pulmonary or ocular. Granulomatous inflammation was the dominant histologic pattern and was often accompanied by regional lymph node pigment deposition. Although causality and population‐level risk cannot be determined from largely descriptive data, recognition of phenotype‐ and color‐associated patterns may guide evaluation, including consideration of sarcoidosis screening in papulonodular black tattoo reactions, and supports the development of prospective registries incorporating standardized clinical and pigment‐analytic data.